Build status - In Progress

Study To Assess Efficacy Safety And Pharmacokinetics Of Iptacopan (LNP023) In Participants With Autoimmune Benign Hematological Disorders

Recruiting
99 years or below
All
Phase 2
3 participants needed
1 Location

Brief description of study

The main purpose of this study is to evaluate the efficacy and safety of the investigational drug iptacopan (LNP023) in people with primary ITP or primary CAD. You will be in the study about 6 months with the opportunity to extend the total duration to about 31 months if you respond well to the treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: autoimmune, hematologic disorders
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 850646

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center